DK1740698T3 - Rekombinant modificeret plasmin - Google Patents

Rekombinant modificeret plasmin

Info

Publication number
DK1740698T3
DK1740698T3 DK05737862.2T DK05737862T DK1740698T3 DK 1740698 T3 DK1740698 T3 DK 1740698T3 DK 05737862 T DK05737862 T DK 05737862T DK 1740698 T3 DK1740698 T3 DK 1740698T3
Authority
DK
Denmark
Prior art keywords
domain
recombinant modified
terminal
human plasminogen
polypeptide
Prior art date
Application number
DK05737862.2T
Other languages
English (en)
Inventor
Jennifer Audrey Hunt
Valery Novokhatny
Original Assignee
Talecris Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1740698(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Talecris Biotherapeutics Inc filed Critical Talecris Biotherapeutics Inc
Application granted granted Critical
Publication of DK1740698T3 publication Critical patent/DK1740698T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05737862.2T 2004-04-22 2005-04-21 Rekombinant modificeret plasmin DK1740698T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56447204P 2004-04-22 2004-04-22
PCT/US2005/013562 WO2005105990A2 (en) 2004-04-22 2005-04-21 Recombinantly modified plasmin

Publications (1)

Publication Number Publication Date
DK1740698T3 true DK1740698T3 (da) 2010-10-25

Family

ID=34982338

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05737862.2T DK1740698T3 (da) 2004-04-22 2005-04-21 Rekombinant modificeret plasmin

Country Status (28)

Country Link
US (2) US8034913B2 (da)
EP (2) EP2246417B1 (da)
JP (1) JP5026254B2 (da)
KR (1) KR101161819B1 (da)
CN (2) CN102660564B (da)
AT (1) ATE476502T1 (da)
AU (1) AU2005238464B2 (da)
BR (1) BRPI0510063B8 (da)
CA (1) CA2563675C (da)
CY (1) CY1111650T1 (da)
DE (1) DE602005022692D1 (da)
DK (1) DK1740698T3 (da)
EA (1) EA010784B1 (da)
ES (2) ES2534744T3 (da)
HK (3) HK1099341A1 (da)
HR (1) HRP20100568T1 (da)
IL (1) IL178343A (da)
MA (1) MA28590B1 (da)
MX (1) MXPA06012236A (da)
NO (1) NO338542B1 (da)
NZ (1) NZ550250A (da)
PL (2) PL1740698T3 (da)
PT (2) PT2246417E (da)
RS (1) RS51623B (da)
SI (1) SI1740698T1 (da)
TN (1) TNSN06332A1 (da)
WO (1) WO2005105990A2 (da)
ZA (1) ZA200608498B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005212431B2 (en) 2004-02-11 2010-07-15 Synthon Biopharmaceuticals B.V. Expression of plasminogen and microplasminogen in duckweed
EP2246417B1 (en) 2004-04-22 2015-01-21 Grifols Therapeutics Inc. Recombinantly modified plasmin
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
AU2008331545B2 (en) * 2007-11-29 2014-01-16 Grifols Therapeutics Inc. Recombinantly modified plasmin
EP2297317A4 (en) 2008-06-04 2011-12-07 Talecris Biotherapeutics Inc COMPOSITION, METHOD AND NECESSARY FOR THE PREPARATION OF PLASMINE
HUE025670T2 (en) 2009-03-03 2016-04-28 Grifols Therapeutics Inc A method for producing plasminogen
KR20120050442A (ko) 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
CN108463240A (zh) * 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法
CN108210895A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防动脉粥样硬化及其并发症的药物及其用途
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
TWI684459B (zh) 2016-12-15 2020-02-11 大陸商深圳瑞健生命科學研究院有限公司 一種治療動脈粥樣硬化及其併發症的方法
EP3556384B1 (en) 2016-12-15 2024-04-10 Talengen International Limited Plasminogen for use in treating diabetes
EP4137715A4 (en) 2020-04-13 2024-05-01 Fcc Kk POWER TRANSMISSION DEVICE
KR20230005298A (ko) * 2020-05-11 2023-01-09 탈렌젠 인터내셔널 리미티드 척수성 근위축증의 치료 방법 및 약물
AU2021387774A1 (en) 2020-11-25 2023-06-08 Grifols Worldwide Operations Limited Wound healing
US11964004B2 (en) * 2021-03-31 2024-04-23 Shenzhen Bay Laboratory Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
WO2024018051A1 (en) 2022-07-22 2024-01-25 Grifols Worldwide Operations Limited Stable plasmin compositions for organ preservation and reconditioning

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US6613508B1 (en) * 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
US6312893B1 (en) * 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
EP0868535B9 (en) 1996-01-23 2007-05-09 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
JPH10158300A (ja) * 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
CN1249252C (zh) 1997-07-22 2006-04-05 佳根基因组学公司 通过ms使序列数据相关的计算机方法和系统
IL140729A0 (en) * 1998-07-14 2002-02-10 Bristol Myers Squibb Co Lysine binding fragments of angiostatin, pharmaceutical compositions containing the same and processes for the preparation thereof
EP1117437B1 (en) * 1998-09-29 2006-12-27 Leuven Research & Development vzw Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
US6969515B2 (en) * 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6664112B2 (en) * 2000-06-02 2003-12-16 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
DE60131450T2 (de) * 2000-12-21 2008-10-16 Thrombogenics N.V. Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle
WO2003054232A2 (en) 2001-12-13 2003-07-03 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US20050124036A1 (en) * 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
US7776026B2 (en) * 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
EP2246417B1 (en) 2004-04-22 2015-01-21 Grifols Therapeutics Inc. Recombinantly modified plasmin
WO2007047874A2 (en) 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
AU2008331545B2 (en) 2007-11-29 2014-01-16 Grifols Therapeutics Inc. Recombinantly modified plasmin

Also Published As

Publication number Publication date
EP1740698B1 (en) 2010-08-04
RS51623B (en) 2011-08-31
EA010784B1 (ru) 2008-10-30
CA2563675C (en) 2012-08-28
CA2563675A1 (en) 2005-11-10
US20100304465A1 (en) 2010-12-02
EA200601950A1 (ru) 2007-02-27
CY1111650T1 (el) 2015-10-07
BRPI0510063B1 (pt) 2020-03-17
JP2007533327A (ja) 2007-11-22
JP5026254B2 (ja) 2012-09-12
CN102660564A (zh) 2012-09-12
NO20065050L (no) 2006-11-03
ES2349555T3 (es) 2011-01-05
MXPA06012236A (es) 2007-01-31
EP1740698A2 (en) 2007-01-10
EP2246417A1 (en) 2010-11-03
HK1175812A1 (en) 2013-07-12
NO338542B1 (no) 2016-09-05
ZA200608498B (en) 2008-07-30
KR101161819B1 (ko) 2012-07-03
NZ550250A (en) 2009-05-31
EP2246417B1 (en) 2015-01-21
PL2246417T3 (pl) 2015-06-30
PL1740698T3 (pl) 2011-01-31
BRPI0510063A (pt) 2008-03-11
DE602005022692D1 (de) 2010-09-16
US8034913B2 (en) 2011-10-11
US8420079B2 (en) 2013-04-16
CN1961070A (zh) 2007-05-09
MA28590B1 (fr) 2007-05-02
BRPI0510063B8 (pt) 2021-05-25
IL178343A0 (en) 2007-02-11
IL178343A (en) 2010-11-30
AU2005238464A1 (en) 2005-11-10
ES2534744T3 (es) 2015-04-28
PT2246417E (pt) 2015-05-05
WO2005105990A2 (en) 2005-11-10
TNSN06332A1 (en) 2008-02-22
CN102660564B (zh) 2013-05-08
WO2005105990A3 (en) 2006-01-12
SI1740698T1 (sl) 2010-11-30
US20110318812A1 (en) 2011-12-29
HK1099341A1 (en) 2007-08-10
PT1740698E (pt) 2010-11-02
HRP20100568T1 (hr) 2010-11-30
KR20070006918A (ko) 2007-01-11
AU2005238464B2 (en) 2011-01-27
ATE476502T1 (de) 2010-08-15
HK1150242A1 (en) 2011-11-11

Similar Documents

Publication Publication Date Title
DK1740698T3 (da) Rekombinant modificeret plasmin
NZ593837A (en) Recombinantly modified plasmin
Bode The structure of thrombin: a janus-headed proteinase
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
Hata et al. Domain II of m-calpain is a Ca2+-dependent cysteine protease
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
ATE463512T1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
Sanchez et al. A novel fibrinolytic metalloproteinase, barnettlysin-I from Bothrops barnetti (Barnett s pitviper) snake venom with anti-platelet properties
WO2007047874A3 (en) Recombinantly modified plasmin
ATE548380T1 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
ATE277172T1 (de) Rekombinante blutgerinnungsproteasen
HUP0400458A2 (hu) Kobalaminkötő fehérjéket expresszáló transzgenikus növények
Castro et al. Current status of snake venom thrombin-like enzymes
Oyama et al. Amino acid sequence of a thrombin like enzyme, elegaxobin, from the venom of Trimeresurus elegans (Sakishima-habu)
ATE345383T1 (de) Säugeradhäsionprotease
DE60336265D1 (de) Inhibitoren der enzymaktivität der endooligopeptidase a (eopa) und ihre verwendungen
NO20082864L (no) Nytt polypeptid med esteraseaktivitet og rekombinant esterase samt anvendelse derav
Oyama et al. Amino acid sequence of a thrombin like enzyme, elegaxobin II, from the venom of Trimeresurus elegans (Sakishima-Habu)
Oyama et al. Substrate specificity of two thrombin like enzymes (elegaxobin, elegaxobin II) from the venom of Trimeresurus elegans (Sakishima-habu), using neutralizing antibody
ATE460476T1 (de) Menschliche protein phosphatase mit ef-hände-1 (ppef-1)- ähnliches genvariant assoziert mit t- zellen lymphoblastisches lymphom